Literature DB >> 17644874

A descriptive study of individuals with membranoproliferative glomerulonephritis.

Der-Fa Lu1, Ann Marie McCarthy, Lynne D Lanning, Connie Delaney, Craig Porter.   

Abstract

OBJECTIVE: Membranoproliferative Glomerulonephritis (MPGN) is one of a group of glomerulonephritides that often begins in childhood and progresses to renal failure. The purpose of this paper is to describe the initial results of a patient-driven database on individuals with MPGN. SAMPLE/
SETTING: Patients with MPGN Types I, II, and III and their family members were recruited to this survey study.
DESIGN: A population survey design was used.
METHODS: A survey was developed for this study that obtained information from the individual with MPGN or a guardian on: patient information, family/patient health history, history of PGN, medications, course of MPGN, history of dialysis, and history of transplant. Surveys were completed either on-line or in paper format.
RESULTS: Fifty-nine individuals who are primarily white (80%) and female (61%) with MPGN Type II (52%) participated in this study. The average age of onset of MPGN in this sample was 12 years. Ten (71%) of the total 14 patients with onset of less than 10y ears of age were female. Among these 10 female, 8 (80%) were diagnosed with MPGN II and developed end stage renal disease.
CONCLUSION: Health screenings for blood pressure, urinary dipstick for both proteinuria and hematuria play important roles in early detection for MPGN. Nurses must provide emotional and information support to this population.

Entities:  

Mesh:

Year:  2007        PMID: 17644874

Source DB:  PubMed          Journal:  Nephrol Nurs J        ISSN: 1526-744X            Impact factor:   0.959


  10 in total

1.  Allelic variants of complement genes associated with dense deposit disease.

Authors:  Maria Asuncion Abrera-Abeleda; Carla Nishimura; Kathy Frees; Michael Jones; Tara Maga; Louis M Katz; Yuzhou Zhang; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

2.  Clinical features and outcomes of 98 children and adults with dense deposit disease.

Authors:  Der-Fa Lu; Mikyung Moon; Lynne D Lanning; Ann Marie McCarthy; Richard J H Smith
Journal:  Pediatr Nephrol       Date:  2011-11-22       Impact factor: 3.714

Review 3.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

4.  Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.

Authors:  Yuzhou Zhang; Carla M Nester; Danniele G Holanda; Henry C Marsh; Russell A Hammond; Lawrence J Thomas; Nicole C Meyer; Lawrence G Hunsicker; Sanjeev Sethi; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2013-08-01       Impact factor: 10.121

5.  Causes of alternative pathway dysregulation in dense deposit disease.

Authors:  Yuzhou Zhang; Nicole C Meyer; Kai Wang; Carla Nishimura; Kathy Frees; Michael Jones; Louis M Katz; Sanjeev Sethi; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

6.  Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.

Authors:  Karsten Häffner; Stefan Michelfelder; Martin Pohl
Journal:  Pediatr Nephrol       Date:  2015-05-19       Impact factor: 3.714

7.  C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.

Authors:  Edwin K S Wong; Kevin J Marchbank; Hannah Lomax-Browne; Isabel Y Pappworth; Harriet Denton; Katie Cooke; Sophie Ward; Amy-Claire McLoughlin; Grant Richardson; Valerie Wilson; Claire L Harris; B Paul Morgan; Svetlana Hakobyan; Paul McAlinden; Daniel P Gale; Heather Maxwell; Martin Christian; Roger Malcomson; Timothy H J Goodship; Stephen D Marks; Matthew C Pickering; David Kavanagh; H Terence Cook; Sally A Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2021-09-22       Impact factor: 8.237

Review 8.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

Review 9.  New approaches to the treatment of dense deposit disease.

Authors:  Richard J H Smith; Jessy Alexander; Paul N Barlow; Marina Botto; Thomas L Cassavant; H Terence Cook; Santiago Rodriguez de Córdoba; Gregory S Hageman; T Sakari Jokiranta; William J Kimberling; John D Lambris; Lynne D Lanning; Vicki Levidiotis; Christoph Licht; Hans U Lutz; Seppo Meri; Matthew C Pickering; Richard J Quigg; Angelique L Rops; David J Salant; Sanjeev Sethi; Joshua M Thurman; Hope F Tully; Sean P Tully; Johan van der Vlag; Patrick D Walker; Reinhard Würzner; Peter F Zipfel
Journal:  J Am Soc Nephrol       Date:  2007-08-05       Impact factor: 10.121

Review 10.  Regulating complement in the kidney: insights from CFHR5 nephropathy.

Authors:  Daniel P Gale; Matthew C Pickering
Journal:  Dis Model Mech       Date:  2011-11       Impact factor: 5.758

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.